Newron Pharmaceuticals S.p.A. | Finanzwire

Basculer en Français

10056	Companies
205532	Keywords
135772	Articles
108967	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 03/20/2026 at 07:05, 8 hours 30 minutes ago

Newron Pharmaceuticals to Present at SIRS 2026

Newron Pharmaceuticals Evenamide Treatment-resistant Schizophrenia Glutamate Modulation Schizophrenia Research
PRESS RELEASE

published on 03/20/2026 at 07:00, 8 hours 35 minutes ago

Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
Newron Pharmaceuticals S.p.A. to present at SIRS 2026 Congress on glutamatergic modulation in treatment-resistant schizophrenia

Schizophrenia Newron Pharmaceuticals Congress Glutamatergic Modulation SIRS
BRIEF

published on 03/19/2026 at 07:05, 1 day 8 hours ago

Newron Pharmaceuticals Extends Loan Repayment with EIB

European Investment Bank Newron Pharmaceuticals Evenamide Finance Contract ENIGMA-TRS Phase III
PRESS RELEASE

published on 03/19/2026 at 07:00, 1 day 8 hours ago

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract
Newron Pharmaceuticals S.p.A. announces agreement with EIB to extend 2018 Finance Contract tranche repayment dates to June 28, 2028, focusing on lead drug candidate evenamide for treatment-resistant schizophrenia

Agreement Newron Pharmaceuticals Evenamide EIB Finance Contract
BRIEF

published on 03/18/2026 at 07:05, 2 days 8 hours ago

Newron Pharmaceuticals Announces Board Nominee Changes

Board Of Directors Annual General Meeting Newron Pharmaceuticals George Garibaldi Paolo Zocchi
PRESS RELEASE

published on 03/18/2026 at 07:00, 2 days 8 hours ago

Newron announces nominations to its Board of Directors at upcoming Annual General Meeting
Newron Pharmaceuticals S.p.A. announces nominations for new Board members and resignations of current members ahead of its Annual General Meeting. Full agenda to be released on March 24, 2026

Board Of Directors Annual General Meeting Nominations Newron Pharmaceuticals Resignations
BRIEF

published on 02/16/2026 at 17:50, 1 month 3 days ago

Newron Pharmaceuticals Secures EUR 38 Million for Phase III Evenamide Program

Financing Newron Pharmaceuticals Evenamide Phase III Trials Treatment-resistant Schizophrenia
PRESS RELEASE

published on 02/16/2026 at 17:45, 1 month 3 days ago

Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
Newron secures up to EUR 38 million from investors for Phase III Evenamide Program, extending cash runway. Company aims to develop evenamide as add-on therapy for treatment-resistant schizophrenia

Financing Schizophrenia Newron Pharmaceuticals Phase III Evenamide Program
BRIEF

published on 02/03/2026 at 07:05, 1 month 17 days ago

Newron Pharmaceuticals Highlights Benefits of Evenamide for Schizophrenia

Clinical Trials Schizophrenia Newron Pharmaceuticals Evenamide Treatment-resistant
PRESS RELEASE

published on 02/03/2026 at 07:00, 1 month 17 days ago

Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Newron Pharmaceuticals S.p.A. announces publication highlighting Evenamide as adjunctive treatment in schizophrenia. Scientific evidence supports unique approach

Schizophrenia Publication Newron Pharmaceuticals Evenamide Adjunctive Treatment

1 2 ... 7

Accesswire

Published on 03/20/2026 at 13:30, 2 hours 5 minutes ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 3 hours 5 minutes ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/20/2026 at 12:00, 3 hours 35 minutes ago

Organto Foods Inc. Announces Marketing Engagements with VSA Capital Limited and Venture Liquidity Partner Ltd.
Published on 03/20/2026 at 03:10, 12 hours 25 minutes ago

Future Fuels Announces Filing of Amended and Restated Life Offering Document
Published on 03/20/2026 at 00:20, 15 hours 15 minutes ago

Prospect Ridge To Host Investor Webinar With Presentation And Audience Q&A

View all ACCESSWIRE

EQS Group

Published on 03/20/2026 at 15:25, 10 minutes ago

TCL is a "Doer": Embedding ESG to Create Positive Impact across the Global Value Chain
Published on 03/20/2026 at 14:49, 46 minutes ago

EQS-Adhoc: H&R GmbH & Co. KGaA: Preliminary Financial Results for 2025
Published on 03/20/2026 at 14:29, 1 hour 6 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 03/20/2026 at 14:28, 1 hour 7 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 03/20/2026 at 14:27, 1 hour 8 minutes ago

Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc

Les Echos

Published on 03/19/2026 at 18:00, 21 hours 35 minutes ago

Filing of the 2025 Universal Registration Document
Published on 03/19/2026 at 15:00, 1 day ago

Statement Accor
Published on 03/19/2026 at 08:45, 1 day 6 hours ago

Deezer and Sonos renew and expand long-term collaboration
Published on 03/19/2026 at 07:00, 1 day 8 hours ago

bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe
Published on 03/19/2026 at 07:00, 1 day 8 hours ago

2025 Annual results and new strategic signature

View all LES ECHOS COMFI WIRE